Breaking News Instant updates and real-time market news.

MRK

Merck

$73.76

-0.56 (-0.75%)

16:15
12/19/18
12/19
16:15
12/19/18
16:15

FDA approve's Merck's Keytruda in patients with recurring carcinoma

Merck announced that the FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, based on the results of the Cancer Immunotherapy Trials Network's CITN-09/KEYNOTE-017 trial. In this Phase 2 trial of 50 patients with recurrent locally advanced or metastatic MCC who had not received prior systemic therapy for their advanced disease, KEYTRUDA monotherapy demonstrated an objective response rate of 56 percent, with a complete response rate of 24 percent and a partial response rate of 32 percent. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Patients received KEYTRUDA 2 mg/kg every three weeks until unacceptable toxicity or disease progression that was symptomatic, rapidly progressive, required urgent intervention, occurred with a decline in performance status, or was confirmed at least four weeks later with repeat imaging. Patients without disease progression were treated for up to 24 months. Assessment of tumor status was performed at 13 weeks followed by every nine weeks for the first year and every 12 weeks thereafter. The major efficacy outcome measures were objective response rate and duration of response as assessed by blinded independent central review per RECIST v1.1.

  • 11

    Jan

  • 16

    Feb

MRK Merck
$73.76

-0.56 (-0.75%)

11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Earnings
Philip Morris lowers FY19 EPS view to 'at least $4.73' from 'at least $4.94' »

Consensus $5.21. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Recommendations
Netflix analyst commentary  »

KeyBanc lowers estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NBRV

Nabriva Therapeutics

$2.01

0.08 (4.15%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Conference/Events
Nabriva Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

BBIO

BridgeBio

$17.92

-0.6 (-3.24%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
BridgeBio reports preclinical data on infigratinib in treating achondroplasia »

BridgeBio Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.28

-1.37 (-0.67%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
Amgen initiated  »

Amgen reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

UCBJY

UCB

$0.00

(0.00%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

$33.42

0.21 (0.63%)

07:04
10/17/19
10/17
07:04
10/17/19
07:04
Earnings
Sandy Spring Bancorp reports Q3 EPS 82c, consensus 80c »

"In the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AUG

Auryn Resources

$1.28

0.09 (7.56%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Hot Stocks
Auryn Resources stakes additional claims at Sombrero North project area »

Auryn Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$45.53

0.33 (0.73%)

, WBA

Walgreens Boots Alliance

$54.66

0.15 (0.28%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Hot Stocks
Centene, Walgreens Boots Alliance, RxAdvance announce partnership »

Centene (CNC), Walgreens…

CNC

Centene

$45.53

0.33 (0.73%)

WBA

Walgreens Boots Alliance

$54.66

0.15 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

MIST

Milestone Pharmaceuticals

$18.75

0.25 (1.35%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Conference/Events
Milestone Pharmaceuticals management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PM

Philip Morris

$79.12

0.8 (1.02%)

07:02
10/17/19
10/17
07:02
10/17/19
07:02
Earnings
Philip Morris reports Q3 adjusted EPS $1.43, consensus $1.36 »

Reports Q3 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

MDGL

Madrigal Pharmaceuticals

$86.78

-0.49 (-0.56%)

07:00
10/17/19
10/17
07:00
10/17/19
07:00
Conference/Events
Madrigal Pharmaceuticals management to meet with Oppenheimer »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ALXN

Alexion

$99.41

-5.435 (-5.18%)

06:58
10/17/19
10/17
06:58
10/17/19
06:58
Initiation
Alexion initiated  »

Alexion reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:58
10/17/19
10/17
06:58
10/17/19
06:58
Hot Stocks
PPG CEO says 'we made excellent progress executing on our key initiatives' »

"We delivered strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

MNST

Monster Beverage

$56.54

0.27 (0.48%)

06:57
10/17/19
10/17
06:57
10/17/19
06:57
Downgrade
Monster Beverage rating change  »

Monster Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$4.71

-0.15 (-3.09%)

06:57
10/17/19
10/17
06:57
10/17/19
06:57
Conference/Events
Fulcrum Therapeutics management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

TSN

Tyson Foods

$81.87

-1.85 (-2.21%)

06:57
10/17/19
10/17
06:57
10/17/19
06:57
Hot Stocks
Tyson Fresh Meats to prohibit ractopamine use »

In an effort to meet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GPRK

GeoPark

$17.95

-0.18 (-0.99%)

06:56
10/17/19
10/17
06:56
10/17/19
06:56
Hot Stocks
GeoPark reports Q3 operational results »

GeoPark reported an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDX

Ardelyx

$4.34

-0.05 (-1.14%)

06:55
10/17/19
10/17
06:55
10/17/19
06:55
Conference/Events
Ardelyx to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:54
10/17/19
10/17
06:54
10/17/19
06:54
Earnings
PPG sees FY19 adjusted EPS $6.17-$6.27, consensus $6.24 »

"As we look ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SAM

Boston Beer

06:53
10/17/19
10/17
06:53
10/17/19
06:53
Upgrade
Boston Beer rating change  »

Cowen upgrades Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PPG

PPG

$118.89

0.665 (0.56%)

06:52
10/17/19
10/17
06:52
10/17/19
06:52
Earnings
PPG reports Q3 adjusted EPS $1.67, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.